Nothing Special   »   [go: up one dir, main page]

Cheng et al., 2018 - Google Patents

The association of tau with mitochondrial dysfunction in Alzheimer's disease

Cheng et al., 2018

View HTML
Document ID
1300416299775389261
Author
Cheng Y
Bai F
Publication year
Publication venue
Frontiers in neuroscience

External Links

Snippet

Increasing evidence suggests that abnormally hyperphosphorylated tau plays a vital role in the pathogenesis of Alzheimer's disease (AD). Mitochondrial dysfunction also has a recognized role in the pathophysiology of AD. In recent years, mitochondrial dysfunction has …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Cheng et al. The association of tau with mitochondrial dysfunction in Alzheimer's disease
Muralidar et al. Role of tau protein in Alzheimer's disease: The prime pathological player
Bitto et al. P62/SQSTM1 at the interface of aging, autophagy, and disease
Pérez et al. Contribution of tau pathology to mitochondrial impairment in neurodegeneration
Yan et al. Metabolic dysregulation contributes to the progression of Alzheimer’s disease
Yang et al. The role of insulin/IGF-1/PI3K/Akt/GSK3β signaling in Parkinson's disease dementia
Brandt et al. Microtubule dynamics and the neurodegenerative triad of Alzheimer's disease: The hidden connection
Yang et al. Mitochondrial dynamics: a key role in neurodegeneration and a potential target for neurodegenerative disease
Carelli et al. Optic neuropathies: the tip of the neurodegeneration iceberg
Joppe et al. The contribution of iron to protein aggregation disorders in the central nervous system
Wang et al. Dysregulation of autophagy and mitochondrial function in Parkinson’s disease
Wan et al. Iron deposition leads to hyperphosphorylation of tau and disruption of insulin signaling
Markovinovic et al. Endoplasmic reticulum–mitochondria signaling in neurons and neurodegenerative diseases
Rahman et al. Therapeutic implication of autophagy in neurodegenerative diseases
Collier et al. Is alpha-synuclein loss-of-function a contributor to parkinsonian pathology? Evidence from non-human primates
Das et al. The use of mouse models to understand and improve cognitive deficits in Down syndrome
Sharma et al. Stressed mitochondria: A target to intrude Alzheimer’s disease
Albanese et al. Autophagy and LRRK2 in the aging brain
De Mello et al. Insulin and autophagy in neurodegeneration
Pan et al. APP promotes osteoblast survival and bone formation by regulating mitochondrial function and preventing oxidative stress
Sun et al. Hippocampal synaptic and neural network deficits in young mice carrying the human APOE 4 gene
Todd Potential pathways for circadian dysfunction and sundowning-related behavioral aggression in Alzheimer’s disease and related dementias
Santoni et al. Pathophysiological role of transient receptor potential mucolipin channel 1 in calcium-mediated stress-induced neurodegenerative diseases
Klimczak et al. Parvalbumin interneurons and perineuronal nets in the hippocampus and retrosplenial cortex of adult male mice after early social isolation stress and perinatal NMDA receptor antagonist treatment
Nguyen et al. Disparate effects of lithium and a GSK-3 inhibitor on neuronal oscillatory activity in prefrontal cortex and hippocampus